Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 2 ... cancers in 5-7 months. Rats bearing estradiol-induced mammary cancers were treated with tamoxifen for three weeks. Tamoxifen reduced tumor mass, measured ...
2009 NOV 16 ... reactive astrogliosis." "In this study we assessed whether raloxifene and tamoxifen, two selective estrogen receptor modulators, have effects similar to estradiol in ...
2009 NOV 9 ... were performed on 91 patients and laparotomy on 47 patients. Drug treatment consisted of tamoxifen, immunosuppression or both. The median survival was 15 months in patients treated with ...
2009 NOV 9 ... aggressive, particularly for older women with small, slow-growing tumors. Tamoxifen therapy: Tamoxifen is a synthetic hormone that can be ...
2009 NOV 2 ... hormone receptor-positive breast cancer patients who were treated with adjuvant tamoxifen therapy," investigators in Vienna, Austria report. "We determined the ...
2009 NOV 23 ... at 12 and 24 months, we evaluated factors (duration and type of aromatase inhibitor, tamoxifen use, age, time since menopause, body mass index, T-score) that might influence BMD at ...
2009 NOV 23 ... "To investigate the therapeutic effect of methylselenocysteine (MSC) combined with tamoxifen in MCF7 breast cancer xenograft and the underlying mechanisms. MCF-7 breast cancer ...
2009 NOV 2 ... symptoms. Further, therapies widely used to prevent recurrence in survivors, such as tamoxifen, tend to induce or exacerbate menopausal symptoms." "The aim of this ...
2009 NOV 2 ... activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and...
2009 NOV 9 ... regime and hormonal therapy were anthracycline-based regime (88.1 percent) and tamoxifen (95.8 percent), respectively. The proportion of breast-conserving surgery and usage of ...
2009 NOV 16 ... had hormone-resistant BC defined as HR-positive BC with progression after treatment with tamoxifen and an aromatase inhibitor. Group 2 had HR-negative BC. Tumor response was assessed ...
2009 NOV 23 ... (CYP2D6) plays an important role in the formation of endoxifen, the active metabolite of tamoxifen. In this study the association between the most prevalent CYP2D6 null-allele in ...
2009 NOV 23 ... inhibitors FDA approved for use in the US. All have been shown to be superior to tamoxifen in disease free survival (DFS) in the treatment of both metastatic and early breast ...
2009 NOV 2 ... All patients were randomly assigned to receive 2 years of goserelin, goserelin plus tamoxifen, tamoxifen alone or no endocrine treatment. We studied, ...
2009 NOV 9 ... or clinical suspicion of invasion were excluded. Premenopausal women were treated with tamoxifen and postmenopausal women were treated with letrozole. Pathologic markers of ...
2009 NOV 2 ... According to recent research from Stuttgart, Germany, "The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated ...
2009 NOV 23 ... treatments,' is the subject of a report. "Adjuvant hormone therapy (HT) based on tamoxifen (TX) or aromatase inhibitors (AIs) has become the standard of care for treating hormone ...
2009 NOV 9 ... (AEBS) ligands, such as PBPE (N-pyrrolidino-(phenylmethyphenoxy)-ethanamine,HCl) and tamoxifen, induced differentiation characteristics in breast cancer cells through the accumulation ...
2009 NOV 16 ... of human SphK1 in MCF-7 cells resulted in enhanced cell proliferation and resistance to tamoxifen-induced cell growth arrest and apoptosis....
2009 NOV 9 ... for their pivotal laboratory work that led to a better understanding of how drugs like tamoxifen and raloxifene work on a molecular level to fight and prevent certain breast cancers. ...
